The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Phase I Trial of 177Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer
Abstract
Purpose: To determine the maximum tolerated dose (MTD), toxicity, human anti-J591 response, pharmacokinetics (PK), organ dosimetry, targeting, and biologic activity of 177 Lutetium-labeled anti–prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177 Lu-J591) in patients with androgen-independent prostate cancer (PC). Patients and Methods: Thirty-five patients with progressing androgen-independent PC received 177 Lu-J591. All patients underwent 177 Lu-J591 imaging, PK, and biodistribution determinations. Patients were eligible for up to three retreatments. Results: Thirty-five patients received 177 Lu-J591, of whom 16 received up to three doses. Myelosuppression was dose limiting at 75 mCi/m 2, and the 70-mCi/m 2 dose level was determined to be the single-dose MTD. Repeat dosing at 45 to 60 mCi/m 2 was associated with dose-limiting myelosuppression; however, up to three doses of 30 mCi/m 2 could be safely administered. Nonhematologic toxicity was not dose limiting. Targeting of all known sites of bone and soft tissue metastases was seen in all 30 patients with positive bone, computed tomography, or magnetic resonance images. No patient developed a human anti-J591 antibody response to deimmunized J591 regardless of number of doses. Biologic activity was seen with four patients experiencing ≥ 50% declines in prostate-specific antigen (PSA) levels lasting from 3+ to 8 months. An additional 16 patients (46%) experienced PSA stabilization for a median of 60 days (range, 1 to 21+ months). Conclusion: The MTD of 177 Lu-J591 is 70 mCi/m 2. Multiple doses of 30 mCi/m 2 are well tolerated. Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., & Murphy, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s · Cited by 698
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
Sweat, S. D., Pacelli, A., Murphy, G. P., & Bostwick, D. G. (1998) · Urology · doi:10.1016/s0090-4295(98)00278-7 · Cited by 607
Expression of the prostate-specific membrane antigen.
Israeli, R., Powell, C. T., Corr, J., Fair, W. R., & Heston, W. D. W. (1994) · PubMed · Cited by 601
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
Wright, G. L., Haley, C., Beckett, M. L., & Schellhammer, P. F. (1995) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/1078-1439(95)00002-y · Cited by 591
Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A. K., Navarro, V., Knudsen, B., & Bander, N. H. (1997) · PubMed · Cited by 528
Self-citationConstitutive and antibody-induced internalization of prostate-specific membrane antigen.
Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., Rahmati, R., & Bander, N. H. (1998) · PubMed · Cited by 458
Self-citationO'Donoghue, J. A., Bardiès, M., & Wheldon, T. E. (1995) · PubMed · Cited by 377
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox, S. J., Goris, M. L., Trisler, K. D., Negrin, R. S., Davis, T., Liles, T. M., Grillo-López, A. J., Chinn, P. C., Varns, C., Ning, S., et al. (1996) · PubMed · Cited by 326
Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S. J., & Bander, N. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.154 · Cited by 313
Self-citationBANDER, N. H., TRABULSI, E. J., KOSTAKOGLU, L., YAO, D., VALLABHAJOSULA, S., SMITH-JONES, P., JOYCE, M. A., MILOWSKY, M., NANUS, D. M., & GOLDSMITH, S. J. (2003) · Journal of Urology · doi:10.1097/01.ju.0000091655.77601.0c · Cited by 263
Self-citationRajasekaran, S. A., Anilkumar, G., Oshima, E., Bowie, J. U., Liu, H., Heston, W., Bander, N. H., & Rajasekaran, A. K. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-11-0731 · Cited by 226
Self-citationSmith-Jones, P. M., Vallabahajosula, S., Goldsmith, S. J., Navarro, V., Hunter, C. J., Bastidas, D., & Bander, N. H. (2000) · PubMed · Cited by 212
Self-citationSmith-Jones, P. M., Vallabhajosula, S., Navarro, V., Bastidas, D., Goldsmith, S. J., & Bander, N. H. (2003) · PubMed · Cited by 184
Self-citationIntraperitoneal Radioimmunotherapy of Ovarian Cancer with177Lu-CC49: A Phase I/II Study
Alvarez, R. D., Partridge, E. E., Khazaeli, M. B., Plott, G., Austin, M., Kilgore, L. C., Russell, C. D., Liu, T., Grizzle, W. E., Schlom, J., et al. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1996.4577 · Cited by 181
BANDER, N. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00358-0 · Cited by 162
Self-citationVallabhajosula, S., Kuji, I., Hamacher, K. A., Konishi, S., Kostakoğlu, L., Kothari, P. A., Milowsky, M. I., Nanus, D. M., Bander, N. H., & Goldsmith, S. J. (2005) · PubMed · Cited by 130
Self-citationIntraperitoneal Radioimmunochemotherapy of Ovarian Cancer: A Phase I Study
Meredith, R. F., Alvarez, R. D., Partridge, E. E., Khazaeli, M. B., Lin, C.-Y., Macey, D. J., Austin, J. M., Kilgore, L. C., Grizzle, W. E., Schlom, J., et al. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497801753131381 · Cited by 90
Mulligan, T. S., Carrasquillo, J. A., Chung, Y., Milenic, D. E., Schlom, J., Feuerstein, I., Paik, C. H., Perentesis, P., Reynolds, J. C., & Curt, G. A. (1995) · PubMed · Cited by 86
OʼDonnell, R. T., DeNardo, S. J., Miers, L. A., Lamborn, K. R., Kukis, D. L., DeNardo, G. L., & Meyers, F. J. (2001) · The Prostate · doi:10.1002/pros.10029 · Cited by 68
Vallabhajosula, S., Smith-Jones, P. M., Navarro, V., Goldsmith, S. J., & Bander, N. H. (2003) · The Prostate · doi:10.1002/pros.10281 · Cited by 65
Self-citationArlen, P. M., Gulley, J. L., Dahut, W., Skarupa, L., Morin, S., Pazdur, M. P., Todd, N. R., Panicali, D., Tsang, K. Y., & Schlom, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2522 · Cited by 16
Cited by
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Tagawa, S. T., Milowsky, M. I., Morris, M., Vallabhajosula, S., Christos, P., Akhtar, N. H., Osborne, J., Goldsmith, S. J., Larson, S., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427
Self-citation89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo
Holland, J. P., Divilov, V., Bander, N. H., Smith-Jones, P. M., Larson, S. M., & Lewis, J. S. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076174 · Cited by 418
Self-citationRadiometals for Combined Imaging and Therapy
Cutler, C. S., Hennkens, H. M., Sisay, N., Huclier-Markai, S., & Jurisson, S. S. (2013) · Chemical Reviews · doi:10.1021/cr3003104 · Cited by 395
Metadata
- Authors
- Bander, N. H., Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., & Goldsmith, S. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-07-20
- Volume
- 23
- Issue
- 21
- Pages
- 4591-4601
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1977316337
- Cited by
- 509
- References
- 22
- FWCI
- 18.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.